Considering the functions of IFN-α in immune responses and its clinical use in stage IIB/C melanoma, we tried to investigate whether a prior line of PEG-IFN-α therapy would affect the efficacy of later adjuvant pembrolizumab. This evidence concerns the gene IFNA1 and melanoma.